Brazilian Journal of Anesthesiology
Brazilian Journal of Anesthesiology
Letter to the Editor

Exploring the analgesic effects of pregabalin for post-chikungunya arthralgia: a comparative double-blind study

Rodrigo Souza Rodrigues, Rioko Kimiko Sakata, William Vinicius da Silva, Camila Roberta Raimundo, Camila Fecury Cerqueira, Plinio da Cunha Leal

Downloads: 0
Views: 445


Dear Editor,

Chikungunya represents a debilitating syndrome triggered by a homonymous virus. Its predominant clinical manifestation involves arthralgia coupled with physical limitations, mirroring rheumatoid arthritis. Despite the absence of disease-specific therapies, the joint pain accompanying chikungunya is inflammatory in nature and exhibits neuropathic characteristics. Pregabalin has displayed beneficial effects, even among patients not meeting neuropathic pain criteria. Notably, preceding research underscores the role of cytokines in the development of chikungunya-associated joint disease, akin to that seen in rheumatoid arthritis. This suggests potential benefits from immunomodulatory therapies such as hydroxychloroquine. Given the disease's prevalence and the consequent morbidity, the necessity for more efficacious treatment options for chronic chikungunya-related arthralgia remains unmet.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi: 10.1016/j.bjane.2023.09.002.


1. Rodríguez-Morales AJ, Cardona-Ospina JA, Fernanda Urbano-Garzon S, Sebastian Hurtado-Zapata J. Prevalence of Post-Chikungunya Infection Chronic Inflammatory Arthritis: A Systematic Review and Meta-Analysis: Chronic Inflammatory Rheumatism Following Chikungunya. Arthritis Care Res (Hoboken). 2016;68:1849−58.

2. Ohtori S, Inoue G, Orita S, et al. Efficacy of Combination of Meloxicam and Pregabalin for Pain in Knee Osteoarthritis. Yonsei Med J. 2013;54:1253.

3. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe D, Wozniacka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus. 2010;19:683−8.

4. Guaraldo L, Wakimoto MD, Ferreira H, et al. Treatment of chikungunya musculoskeletal disorders: a systematic review. Expert Rev Anti Infect Ther. 2018;16:333−44.

5. Zaid A, Gerardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S. Review: Chikungunya Arthritis: Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis Rheumatol. 2018;70:484−95. h.

Submitted date:

Accepted date:

6516eb9ba953950e582893f3 rba Articles
Links & Downloads

Braz J Anesthesiol

Share this page
Page Sections